Wells Fargo’s Bicycle Therapeutics BCYC Stock Holding History

Wells Fargo’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$928	Hold	200	–	–	﹤0.01%	6343
2025 Q4	$1.42K	Hold	200	–	–	﹤0.01%	6260
2025 Q3	$1.55K	Hold	200	–	–	﹤0.01%	6216
2025 Q2	$1.39K	Buy	+200	New	+$1.59K	﹤0.01%	6266
2024 Q4	–	Sell	-30	Closed	-$679	–	7061
2024 Q3	$679	Buy	+30	New	+$692	﹤0.01%	6149
2023 Q4	–	Sell	-12	Closed	-$241	–	7593
2023 Q3	$241	Buy	+12	New	+$274	﹤0.01%	6538
2023 Q2	–	Sell	-19	Closed	-$404	–	7583
2023 Q1	$404	Buy	+19	New	+$477	﹤0.01%	6609
2022 Q3	–	Sell	-1	Closed	–	–	6655
2022 Q2	$0	Buy	+1	New	+$21	﹤0.01%	6796
2022 Q1	–	Sell	-6,001	Closed	-$365K	–	7054
2021 Q4	$365K	Sell	6,001 -103	-2%	-$5.68K	﹤0.01%	4914
2021 Q3	$254K	Buy	+6,104	New	+$213K	﹤0.01%	4996

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSK plc London $599M AUM

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's BCYC Position: Q1 2026 in Review

Wells Fargo held its Bicycle Therapeutics (BCYC) position steady in Q1 2026 at 200 shares worth $928. The position accounts for ﹤0.01% of the portfolio, ranked #6343.

Wells Fargo first reported a position in BCYC in Q3 2021 and has held it in 10 quarters since. The position peaked at $365K in Q4 2021. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

Wells Fargo held 200 shares of Bicycle Therapeutics worth $928 as of Q1 2026.
Wells Fargo left its Bicycle Therapeutics share count unchanged in Q1 2026.
Bicycle Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6343 holding.
Wells Fargo first reported a position in Bicycle Therapeutics in Q3 2021 and has held it in 10 quarters since.
Wells Fargo's Bicycle Therapeutics position peaked at $365K in Q4 2021.
98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.